Omeros Announces Webcast Details for Annual Meeting of Shareholders
21 Giugno 2023 - 2:30PM
Business Wire
Omeros Corporation (Nasdaq: OMER), today announced that the
company will host a live webcast of its Annual Meeting of
Shareholders, which will be held virtually on Friday, June 23,
2023, starting at 10:00 a.m. Pacific Time.
A live webcast of the Annual Meeting of Shareholders can be
accessed through www.virtualshareholdermeeting.com/OMER2023. A
general corporate overview and question and answer session is
expected to follow the business portion of the annual meeting.
As described in the Company’s proxy statement, filed May 17,
2023, only shareholders of record as of the close of business on
April 18, 2023 are entitled to vote at the Annual Meeting of
Shareholders and any adjournment or postponement thereof.
Shareholders of record will be able to attend the meeting, vote and
submit questions via the Internet at
www.virtualshareholdermeeting.com/OMER2023 using their 16-digit
control number provided in their proxy card or in the instructions
accompanying their proxy materials.
Guests without a 16-digit control number may also attend the
Annual Meeting by accessing the website listed above but will not
have the option to vote or ask questions.
For those unable to attend the live event, a recording will be
archived and accessible at
https://investor.omeros.com/archived-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy (TA-TMA).
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome.
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing across multiple clinical programs for alternative
pathway-related diseases, including paroxysmal nocturnal
hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more
information about Omeros and its programs, visit
www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621115560/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Grafico Azioni Omeros (NASDAQ:OMER)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Omeros (NASDAQ:OMER)
Storico
Da Giu 2023 a Giu 2024